Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with ...

Eisbach Bio's innovative approach focuses on exploiting the unique genetic vulnerabilities present in solid tumors with deficiencies in certain DNA repair pathways. Eisbach's proprietary ALLOS ...

Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.

Hangzhou Synrx Therapeutics Biomedical Technology Co. Ltd. recently presented the development and characterization of a novel PARG inhibitor, SYN-608, for the potential treatment of tumors ...

These systems specify a "landing pad" in the genome for gene insertion, minimizing variability in gene expression by ...

TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...

Panelists discuss how the PROfound trial (NCT02987543) demonstrated the efficacy and safety of olaparib monotherapy in metastatic prostate cancer patients with homologous recombination repair gene ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.